Stock Track | BAO PHARMA-B Soars 10.57% in Intraday Session on Commercialization Prospects and Revenue Forecasts

Stock Track02-10 12:48

BAO PHARMA-B's stock soared 10.57% during the intraday session, reflecting strong investor interest in the biopharmaceutical company.

The surge appears driven by positive developments in BAO PHARMA's product pipeline, including KJ017 (China's first recombinant human hyaluronidase submitted for market approval), KJ103 (a potentially best-in-class IgG-degrading enzyme for autoimmune diseases), and SJ02 (a long-acting follicle-stimulating hormone for assisted reproduction). These three core products are in commercialization, new drug application review, or late-stage clinical trials, signaling the company's transition from research to commercial stage.

Additionally, a securities firm research report indicates that BAO PHARMA has established a clear commercialization strategy, with products expected to generate significant revenue starting in 2026. KJ017 and SJ02 are forecasted to be primary revenue drivers, while KJ103 is anticipated to contribute from 2027 onward, further boosting investor confidence.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133784238?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 12:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133784238","market":"nz","top_or_hot":-1,"title":"Stock Track | BAO PHARMA-B Soars 10.57% in Intraday Session on Commercialization Prospects and Revenue Forecasts","media":"Stock Track","content":"<p>BAO PHARMA-B's stock soared 10.57% during the intraday session, reflecting strong investor interest in the biopharmaceutical company.</p><p>The surge appears driven by positive developments in BAO PHARMA's product pipeline, including KJ017 (China's first recombinant human hyaluronidase submitted for market approval), KJ103 (a potentially best-in-class IgG-degrading enzyme for autoimmune diseases), and SJ02 (a long-acting follicle-stimulating hormone for assisted reproduction). These three core products are in commercialization, new drug application review, or late-stage clinical trials, signaling the company's transition from research to commercial stage.</p><p>Additionally, a securities firm research report indicates that BAO PHARMA has established a clear commercialization strategy, with products expected to generate significant revenue starting in 2026. KJ017 and SJ02 are forecasted to be primary revenue drivers, while KJ103 is anticipated to contribute from 2027 onward, further boosting investor confidence.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BAO PHARMA-B Soars 10.57% in Intraday Session on Commercialization Prospects and Revenue Forecasts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BAO PHARMA-B Soars 10.57% in Intraday Session on Commercialization Prospects and Revenue Forecasts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-10 12:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAO PHARMA-B's stock soared 10.57% during the intraday session, reflecting strong investor interest in the biopharmaceutical company.</p><p>The surge appears driven by positive developments in BAO PHARMA's product pipeline, including KJ017 (China's first recombinant human hyaluronidase submitted for market approval), KJ103 (a potentially best-in-class IgG-degrading enzyme for autoimmune diseases), and SJ02 (a long-acting follicle-stimulating hormone for assisted reproduction). These three core products are in commercialization, new drug application review, or late-stage clinical trials, signaling the company's transition from research to commercial stage.</p><p>Additionally, a securities firm research report indicates that BAO PHARMA has established a clear commercialization strategy, with products expected to generate significant revenue starting in 2026. KJ017 and SJ02 are forecasted to be primary revenue drivers, while KJ103 is anticipated to contribute from 2027 onward, further boosting investor confidence.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1133784238","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133784238","pubTimestamp":1770698939,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BAO PHARMA-B's stock soared 10.57% during the intraday session, reflecting strong investor interest in the biopharmaceutical company.The surge appears driven by positive developments in BAO PHARMA's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"个股轨迹|宝药业-B盘中暴涨10.57%，因商业化前景及营收预测","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"BAO PHARMA-B's stock soared 10.57% during the intraday session, reflecting strong investor interest in the biopharmaceutical company.The surge appears driven by positive developments in BAO PHARMA's product pipeline, including KJ017 (China's first recombinant human hyaluronidase submitted for market approval), KJ103 (a potentially best-in-class IgG-degrading enzyme for autoimmune diseases), and SJ02 (a long-acting follicle-stimulating hormone for assisted reproduction). These three core products are in commercialization, new drug application review, or late-stage clinical trials, signaling the company's transition from research to commercial stage.Additionally, a securities firm research report indicates that BAO PHARMA has established a clear commercialization strategy, with products expected to generate significant revenue starting in 2026. KJ017 and SJ02 are forecasted to be primary revenue drivers, while KJ103 is anticipated to contribute from 2027 onward, further boosting investor confidence.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133784238","isCrawlerRequest":true}